Table 1

Comparison of levels (mean ± SD) of TTR and RBP in serum and asciticfluid in relation to FIGO-stages and levels of CRP in ovarian cancer patients

serum (μg/mL)

ascitic fluid (μg/mL)

percentage of serum in ascitic fluid


TTR

RBP

TTR

RBP

TTR

RBP


Healthy control n = 20

363.3 ± 105.5

55.8 ± 9.3

-

-

-

-

All Stages ovarian cancer

148.5 ± 96.7

22.5 ± 14.8

1.022 ± 0.239

4.632 ± 1.572

1.0 ± 0.6

26.2 ± 14.9

Stage I/II ovarian cancer

162.5 ± 69.4

34.2 ± 22.3

0.966 ± 0.375

3.580 ± 0.849

0.8 ± 0.6

14.5 ± 9.8

Stage III ovarian cancer

155.6 ± 107.6

19.5 ± 7.5

1.074 ± 0.185

4.800 ± 1.711

1.0 ± 0.6

27.2 ± 11.8

Stage IV ovarian cancer

129.0 ± 96.0

17.4 ± 7.3

0.965 ± 0.241

4.627 ± 1.672

1.2 ± 0.7

32.1 ± 23.3

Ovarian cancer CRP > 40 mg/l

116.0 ± 94.3

14.2 ± 4.3

1.047 ± 0.213

4.736 ± 1.886

1.4 ± 0.7

35.4 ± 17.2

Ovarian cancer CRP < 40 mg/l

166.3 ± 92.1

24.1 ± 12.5

1.005 ± 0.260

4.503 ± 1.415

0.8 ± 0.5

22.3 ± 11.1


All values for ascitic fluid (if available) are significantly different (p < 0.01) from serum value.

Gericke et al. BMC Cancer 2005 5:133   doi:10.1186/1471-2407-5-133

Open Data